Regeneron Pharmaceuticals, Inc. (REGN)

333.34
NASDAQ
Prev Close 333.34
Day Low/High 0.00 / 0.00
52 Wk Low/High 281.89 / 442.00
Exchange NASDAQ
Shares Outstanding 109.28B
Market Cap 36.43B
Div & Yield N.A. (N.A)

Latest News

Alnylam And Regeneron Announce Broad Collaboration To Discover, Develop And Commercialize RNAi Therapeutics Focused On Ocular And Central Nervous System (CNS) Diseases

Alnylam And Regeneron Announce Broad Collaboration To Discover, Develop And Commercialize RNAi Therapeutics Focused On Ocular And Central Nervous System (CNS) Diseases

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Regeneron Pharmaceuticals, Inc.

Disrupt or Be Disrupted: Cramer's 'Mad Money' Recap (Wednesday 3/13/19)

Disrupt or Be Disrupted: Cramer's 'Mad Money' Recap (Wednesday 3/13/19)

Disruptors are among the biggest winners, says Jim Cramer. Companies like Apple and Kraft Heinz need to re-imagine their companies in bold, meaningful and even radical ways.

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2019 With Innovative Ideas On Exoplanets, HIV And A Classic Math Problem

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2019 With Innovative Ideas On Exoplanets, HIV And A Classic Math Problem

Top Award of $250,000 Goes to Ana Humphrey of Virginia in Nation's Oldest and Most Prestigious STEM Competition for High School Seniors

FDA Approves Dupixent® (dupilumab) For Moderate-to-severe Atopic Dermatitis In Adolescents

FDA Approves Dupixent® (dupilumab) For Moderate-to-severe Atopic Dermatitis In Adolescents

Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis

FDA Approves Dupixent® (dupilumab) For Moderate-to-severe Atopic Dermatitis In Adolescents

FDA Approves Dupixent® (dupilumab) For Moderate-to-severe Atopic Dermatitis In Adolescents

* Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis

Regeneron Announces Upcoming Investor Conference Call

Regeneron Announces Upcoming Investor Conference Call

TARRYTOWN, N.Y.

Teva Pharmaceuticals CEO Talks "Trough Year", 2020 Turnaround

Teva Pharmaceuticals CEO Talks "Trough Year", 2020 Turnaround

Teva's CEO explains why 2019 is a trough year for the Israeli pharma company.

Regeneron Announces Upcoming Investor Conference Presentation

Regeneron Announces Upcoming Investor Conference Presentation

TARRYTOWN, N.Y.

Sanofi And Regeneron Offer Praluent® (alirocumab) At A New Reduced U.S. List Price

Sanofi And Regeneron Offer Praluent® (alirocumab) At A New Reduced U.S. List Price

* This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients

Chart of the Day: Regeneron

Weekly Regeneron chart shows a strong breakout.

TheStreet Quant Rating: B (Buy)